Limited has received final approval from the US Food and Drug Administration (FDA) for azacitidine
injection used in the treatment of cancer. “Natco Pharma
Limited is pleased to announce final approval of abbreviated new drug application (ANDA) from the US FDA
for injection, 100 mg per vial, single-dose vial - a generic version of Vidaza
by Celgene Corporation,” said the company in a press release.
Natco and its marketing partner Breckenridge Pharmaceutical Inc (BPI) plan to launch this product in the US market in the near future.
is a prescription anti-cancer chemotherapy drug that is indicated to treat myelodysplastic syndrome (MDS). Vidaza
generated total combined sales of $ 188 million for the twelve-month period ending April, 2017, based on industry sales data.